Esteve, a Spain-based contract development and manufacturing organization (CDMO), has recently completed the purchase of Regis Technologies, a Chicago-based CDMO, to bolster its North American footprint and advance its capabilities. The acquisition not only signifies Esteve’s expansion into the United States but also signifies its commitment to growing its CDMO services for small-molecule active pharmaceutical ingredients (APIs) across the drug development life cycle. Esteve CDMO, operating under the Esteve Química brand, specializes in producing high-quality small-molecule APIs and intermediates, offering advanced services like spray drying and high-potency API (HPAPI) manufacturing.
Regis Technologies, with over 65 years of experience, contributes a wealth of expertise in API manufacturing, analytical services, process research and development, cGMP API manufacturing, chromatography products, and CMC support. This acquisition not only integrates Regis Technologies’ capabilities into Esteve’s offerings but also adds around 70 skilled professionals to Esteve’s US team. The strategic alignment of values between the family-owned companies is emphasized, underscoring their shared commitment to long-term customer value and employee well-being.
The Esteve-Regis deal not only broadens Esteve’s capabilities but also strengthens its rare disease portfolio through additional acquisitions. Esteve recently acquired the rights to Caprelsa (vandetanib) from Sanofi, expanding its oncology portfolio with a treatment for medullary thyroid cancer. Vandetanib, a protein tyrosine kinase inhibitor, hinders tumor growth by blocking tyrosine kinase enzymes, particularly beneficial in managing medullary thyroid carcinoma, a rare neuroendocrine tumor. Esteve’s Chief Scientific & Medical Officer highlighted the significance of this acquisition in enhancing patient care and advancing treatment options for individuals battling this rare form of cancer.
Moreover, Esteve’s commitment to rare diseases extends further with its acquisition of a company specializing in the endocrinology and onco-endocrinology space. This strategic purchase adds three new medications to Esteve’s portfolio aimed at addressing endogenous Cushing’s syndrome and Adrenocortical Carcinoma. By deepening its focus on rare diseases, Esteve solidifies its position as a highly specialized pharmaceutical company dedicated to advancing treatments for underserved patient populations.
In conclusion, Esteve’s acquisition of Regis Technologies marks a significant step in its expansion strategy, fortifying its presence in the US and enhancing its rare disease portfolio. The alignment of values, combined with the shared commitment to innovation and customer-centric solutions, bodes well for the future of the merged entities. Esteve’s recent acquisitions not only signify its dedication to advancing treatment options for rare diseases but also underscore its mission to provide high-quality services and products to the pharmaceutical industry.
Key Takeaways:
– Esteve’s acquisition of Regis Technologies strengthens its US presence and CDMO capabilities, emphasizing its commitment to growth and innovation in the pharmaceutical sector.
– The addition of Caprelsa (vandetanib) to Esteve’s oncology portfolio enhances its rare disease offerings, particularly in the treatment of medullary thyroid cancer, showcasing its dedication to advancing patient care.
– Esteve’s strategic expansion into the rare disease space through additional acquisitions underscores its commitment to developing specialized treatments for underserved patient populations, solidifying its position as a key player in the pharmaceutical industry.
Tags: chromatography
Read more on pharmaceuticalcommerce.com